Ropivacaine Hydrochloride API

Name	Ropivacaine hydrochloride
Chinese name	盐酸罗哌卡因
Cas Number	132112-35-7
Source	India
Qualifications	USDMF/-/-/-/-

Ropivacaine hydrochloride was developed by AstraZeneca, and was approved by the FDA for marketing in September 1996. The domestic approval for marketing was March 2005. Ropivacaine hydrochloride is an aminoamide local anesthetic, which may block the generation and conduction of nerve impulses by increasing the threshold of nerve electrical stimulation, slowing down the propagation of nerve impulses and reducing the rising speed of action potentials. Ropivacaine hydrochloride is a local anesthetic, which has a faster onset than procaine, faster catabolism, and slightly less toxicity than procaine. Clinical research on the analgesic effect of anesthesia after caesarean section found that compared with bupivacaine, the use of ropivacaine hydrochloride has a more significant analgesic effect on caesarean section and the recovery of nerve block is faster, which can effectively reduce the maternal burden. Bed time. In 2018, the total sales of local anesthetics in urban public hospitals nationwide was approximately 1.786 billion yuan, of which ropivacaine hydrochloride injection ranked first with a sales of 490 million yuan. In 2019, the sales of ropivacaine in China's urban public hospitals, county-level public hospitals, urban community centers, and township health centers have exceeded 1.1 billion yuan.

Hot Tags: ropivacaine hydrochloride api, China, suppliers, manufacturers, factory, customized, price, pricelist, in stock, Salmeterol Xinafoate API, Pregabalin API, Aprepitant Aprepitant API, Temozolomide API, Dapoxetine API, Solinasine Succinate API

• Previous: Naloxone Hydrochloride API
• Next: Ethylphenidate API